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Abstract
Background: In the quest of a curative radiotherapy treatment for gliomas new delivery modes are being
explored. At the Biomedical Beamline of the European Synchrotron Radiation Facility (ESRF), a new spatially-
fractionated technique, called Minibeam Radiation Therapy (MBRT) is under development. The aim of this work is
to compare the effectiveness of MBRT and broad-beam (BB) synchrotron radiation to treat F98 glioma rat cells. A
dose escalation study was performed in order to delimit the range of doses where a therapeutic effect could be
expected. These results will help in the design and optimization of the forthcoming in vivo studies at the ESRF.
Methods: Two hundred thousand F98 cells were seeded per well in 24-well plates, and incubated for 48 hours
before being irradiated with spatially fractionated and seamless synchrotron x-rays at several doses. The percentage
of each cell population (alive, early apoptotic and dead cells, where either late apoptotic as necrotic cells are
included) was assessed by flow cytometry 48 hours after irradiation, whereas the metabolic activity of surviving
cells was analyzed on days 3, 4, and 9 post-irradiation by using QBlue test.
Results: The endpoint (or threshold dose from which an important enhancement in the effectiveness of both
radiation treatments is achieved) obtained by flow cytometry could be established just before 12 Gy in the two
irradiation schemes, whilst the endpoints assessed by the QBlue reagent, taking into account the cell recovery,
were set around 18 Gy in both cases. In addition, flow cytometric analysis pointed at a larger effectiveness for
minibeams, due to the higher proportion of early apoptotic cells.
Conclusions: When the valley doses in MBRT equal the dose deposited in the BB scheme, similar cell survival ratio
and cell recovery were observed. However, a significant increase in the number of early apoptotic cells were found
48 hours after the minibeam radiation in comparison with the seamless mode.
Background
Gliomas are among the most frequent primary brain
tumors in adults, with an incidence of approximately 5/
100,000 among the general population [1], and despite
significant advances in cancer therapy, treatment of
high-grade gliomas is only palliative.
A radical radiotherapy treatment of radioresistant
tumors would require the development of new techni-
ques allowing to spare the sensitive surrounding normal
tissue.
Since 1990s synchrotron radiation has become one of
the most valuable tools in experimental radiotherapy in
the quest for a radical treatment for gliomas. Synchro-
tron sources are ideal for spatially fractionated techni-
ques such as Microbeam Radiation Therapy (MRT) and
Minibeam Radiation Therapy (MBRT), currently under
development at the European Synchrotron Radiation
Facility -ESRF- in Grenoble, France. The reason is that
synchrotron beams possess two relevant features: a neg-
ligible divergence allowing to have sharp defined irradia-
tion edges, and a 106 times higher fluence of x-rays than
standard medical irradiators, which permits to avoid the
beam smearing to the cardiosynchronous pulsations [2].
These two innovative techniques, MRT and MBRT,
are based on the dose-volume effect: the smaller the
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irradiated volume is, the higher the dose tolerances of
the healthy tissue are [3]. The beam width ranges from
25 to 100 μm in MRT, whereas in MBRT beams of 500
- 700 μm width are employed. That is to say, one or
two orders of magnitude thinner than the ones used in
conventional radiotherapy. The energy spectrum
employed ranges from 50 to 500 keV, and with a mean
energy at around 100 keV [4].
The dose is spatially fractionated: high doses are deliv-
ered in one fraction by using arrays of intense parallel
beams. The interbeam separation is 200 μm or 400 μm in
the case of MRT and 600 μm in MBRT. The dose profiles
consist of peak and valleys, with high doses in the beams
paths and low doses in the spaces between them [5].
During the last two decades many in vivo experiments
have shown the sparing effect provided by MRT in the
healthy tissue of the central nervous system (CNS)
[6-10]. The spatial fractionation of the dose would pro-
vide a further gain in tissue sparing due to a biological
repair of the microscopic lesions by the minimally irra-
diated contiguous cells [6,11].
In parallel it was observed that the tumor area is irre-
versibly damaged by the extremely high doses deposited
on it [8,11,12] by using microbeams.
The thin microbeams (and their associated small beam
spacing) need high dose rates, only available at synchro-
trons nowadays. This limits their widespread clinical
implementation. In addition, the high lateral scattering
produced by beam energies higher than 200 keV would
lead to the loose of the healthy tissue sparing [5]. The
requirement of low-energy beams limit the dose pene-
tration to the tissue.
To overcome those drawbacks MBRT has been
recently proposed by Dilmanian et al. [13], also based
on the dose-volume effect explained before. The
increase of the thickness of the beams up to 0.68 mm,
with a center-to-center (c-t-c) distance between them
corresponding to the double of this value, might result
in some advantages over the MRT such as [14]: i) The
dose profiles of minibeams are not as vulnerable as
those of microbeams to beam smearing from cardiosyn-
chronous brain tissue pulsation [2]. Hence the high dose
rate of synchrotron sources is not needed, and it makes
feasible their forthcoming clinical implementation with
proper technical improvements. ii) In MBRT, the use of
higher beam energy is feasible [5] resulting in a lower
entrance dose to deposit the same integrated dose
within the tumor with respect to MRT.
In a first in vivo experiment performed by Dilmanian
and coworkers [13], minibeams as thick as 0.68 mm
seemed to keep (part) of the sparing effect observed in
MRT, supporting a potential application of minibeams
to treat tumors with minimal damage to the surround-
ing healthy tissues.
For the aforementioned reasons, MBRT has been
recently implemented at the ESRF ID17 Biomedical
Beamline [14].
This work is framed in first studies of the effectiveness
of MBRT for the treatment of gliomas. Although the
results of in vitro studies cannot replace in vivo works,
they should be performed a priori in order to design
better animal experiments, and delimit to some extent
the range of doses where the therapeutic window for a
new radiation treatment could be expected.
To the best of our knowledge, although until the
moment there is a lack of published data concerning in
vitro experiments with MBRT. Nevertheless, this kind of
experiments based on cell cultures play an important role
under the point of view of the ethical standards based on
the so-called three Rs: Reduce the number of animals in
each experiment, Refine the methodologies used on
them, and Replace the animals for cells whenever possi-
ble in order to assess the endpoint of a radiation treat-
ment, providing more information previously in vitro
before to scale up this to a small animals. Moreover, cells
studies are required to quantify the apoptotic events after
the irradiations by using techniques such as flow cytome-
try, only feasible in in vitro experiments [15].
The main aim of this work was to assess the endpoint,
or threshold dose from which an important enhance-
ment in the effectiveness is achieved for both, mini-
beams and seamless irradiations on F98 cell cultures.
Due to the fact that the ratio of post-irradiated living
cells obtained from flow cytometric analises is not pro-
portional to their recovery ability with time, the meta-
bolic activity of this sort of cells at different days was
also analyzed for each deposited dose and irradiation
mode.
Methods
Cell line and culture conditions
In current experimental neuro-oncology many wide-
spread cell rat models are used [16], being 9L gliosar-
coma and F98 glioma the most extended cell lines
[17,18].
The F98 rat glioma cell line was obtained from the
American Type Culture Collection. This kind of tumor
cells has an infiltrative pattern of growth within the
brain when they are inoculated as a tumor model, and
also a weakly immunogenic response. For these charac-
teristics, F98 simulates human glioblastoma multiforme
[16]. In the experiments, F98 cells were cultured in
flasks of 25 cm2 on Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 1% penicillin/
streptomycin, and with 10% fetal calf serum to reach
confluence. Two hundred thousand F98 cells were
seeded per well in 24-well plates and incubated for
48 hours at 37°C.
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All the supernatants were removed and replaced by
fresh medium just after irradiation.
X-ray irradiations
Both minibeam and seamless in vitro irradiations were
carried out at the ESRF ID17 biomedical beamline
where the x-rays source consists in a wiggler with 15
cm of period, and a maximum magnetic field of 1.6 T.
It is located 40 meters far from the sample. The dose
rate at the target position is 5350 Gy s-1 [14].
Fifty per cent of the previously seeded plates were
irradiated vertically in front of the beam at different
doses with one array of minibeams of 600 μm-width,
with a center-to-center distance of 1200 μm, and cover-
ing a field of 2 × 2 cm2. The remaining plates were irra-
diated with a seamless beam configuration.
Monte Carlo simulations and dose calculations
The dose deposited on the cells monolayer was assessed
both theoretically (Monte Carlo simulations) and experi-
mentally. In order to reduce an extra dose deposition on
cells from the scattering of filled wells contiguously, the
seeding well configuration for each plate was the same
as those represented in Figure 1. Moreover, to have
similar valley doses like the ones expected in the forth-
coming in vivo experiments with small animals the wells
were filled up with medium, remaining the cells on the
bottom, at 1.7 cm depth. If the cell layer had been
irradiated directly, in the absence of medium, the peak-
to-valley dose ratio (PVDR) would have been much
higher than the one calculated for the in vivo experi-
ments with rats, due to reduced scattering filling the
valleys [4].
Absolute dose at 1.7 cm depth was measured with an
ionization chamber (PTW 31002 [http://www.ptw.de])
in a water-equivalent RW3 material (Goettingen White
Water) with a seamless field of 2 × 2 cm2. The dose
measured in this broad field configuration was con-
verted to peak doses at 1.7 cm by using the phantom
scatter factor. That factor was been assessed by using
Monte Carlo simulations (PENELOPE 2006 [19]) and
verified experimentally with radiochromic films (Interna-
tional Specialty Products, http://online1.ispcorp.com).
The plate geometry was modeled using the geometry
package in PENELOPE. Monte Carlo simulations for
peak and valley doses assessment were performed.
Experimental validation of the calculations was carried
out by using radiochromic films placed at different
depths in the water-equivalent RW3 material phantom.
A dose escalation study was performed with both,
MBRT and broad beam (BB).
Although some MRT studies indicate that the tumor
control depends both on the peak and valley doses
[8,20], this still needs to be confirmed in MBRT studies
(not the scope of this work). In this first study the effec-
tiveness of MBRT and BB irradiations was compared by
taking MBRT valley doses in as a reference.
It was considered relevant to start assessing first which
is the range of valley doses required to produce tumor
ablation. Those results are expected to help designing
the first in vivo experiment, the objective being the
assessment of the dose tolerances of the rat brain. All
this would allow delimiting the position of the possible
therapeutic window for gliomas in this new radiotherapy
approach (to be confirmed in in vivo studies) and its
comparison with conventional methods.
In addition the higher the valley doses, the higher the
density of lesions in the tumor. Therefore, it could be
hypothesized that a higher tumor control probability is
expected, to be confirmed in future animal studies.
Hence an escalation taking as a reference the valley
dose seemed justified. Tables 1 and 2 report the doses
in MBRT and BB respectively, evaluated in this work.
Figure 1 24-well plate’s picture (partially). Picture corresponding
to a 24-well plate like those employed in the irradiations, either for
MBRT or seamless irradiations. The verification of the dose assessed
was done by using radiochromic films just above the wells as it is
shown.
Table 1 Peak doses, valley doses, and integrated doses
for minibeam irradiation:
Peak dose (Gy) 63 126 189 252 315 420
Valley dose (Gy) 6 12 18 24 30 40
Integrated dose (Gy) 34.5 69.0 103.5 138.0 172.5 230.0
The peak and valley doses (standard error, SE = ± 5%) delivered with MBRT.
The integrated dose represents the mean dose deposited between the peak
and the valley regions.
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The integrated dose was directly calculated as an aver-
age of each peak and valley doses (Table 1).
Techniques used post-irradiation to assess cellular
damage
Flow cytometry for the analysis and quantification of post-
irradiated cell populations (alive, early apoptotic and dead
cells)
This technique is based on detection of apoptosis-asso-
ciated changes in distribution of an inner plasmatic
membrane phospholipid called phosphatidylserine (PS).
Early in apoptosis PS undergoes translocation to the
external surface of the plasmatic membrane. By using
the protein annexin V, which has a high affinity for the
negatively charged PS, conjugated with a fluorochrome
such as fluorescein isothiocyanate (FITC), it is possible
to identify apoptosis in post-irradiated cells [15,21]. In
order to detect also late apoptotic and necrotic cells,
FITC-conjugated annexin V was used in combination
with a DNA staining with propidium iodide (PI)
(Annexin-V-FLUOS staining kit, Roche). Most of the
flow cytometric methods do not allow for a clear dis-
tinction between late apoptotic and necrotic cells, due
to in both cases, the dead cells are double-stained with
annexin-V-FITC and PI.
To obtain the correct percentage of each cell popula-
tion 48 hours after irradiation, it was essential to add
the floating cells to the trypsinized ones and mesure all
them (105 cells at least), before performing flow cytome-
try by using a FACS Calibur (Becton Dickinson). More-
over, cells of minibeam’s peak and valley regions were
analyzed together. The final data about non-apoptotic
live cells (FITC-negative, PI-negative), early apoptotic
cells (FITC-positive, PI-negative), and late apoptotic
cells as well as necrotic (FITC-positive, PI-positive) were
analyzed with WinMDI 2.9 free software (Scripps
research instituteville, La Jolla CA, USA). The popula-
tion was gated in order to eliminate debris.
QBlue assay for the metabolic evaluation of surviving cells
QBlue cell viability test (QBlue Cell Viability Assay kits,
BioChain, USA) is based on the conversion of a non
fluorescent reagent (resazurin) into a high fluorescent
product (resorufin), upon mitochondrial reduction by
the remaining living cells. To perform this test, the
remaining living cells just after each irradiation were
trypsinized and counted. In a 96-well plate, ten thou-
sand cells were seeded per well and incubated at 37°C
in order to check cell recovery at days three, four, and
nine after irradiation, with a Wallac Fluorometry plate
reader (excitation wavelength at 550 nm and emission at
615 nm).
Since the supernatants containing either early apopto-
tic as dead cells were not included, the metabolic activ-
ity measured was only due to the remaining living cells
after irradiation.
Moreover, cells used to perform the QBlue test were
irradiated in different 24-well plates than those analyzed
by flow cytometry.
Statistical evaluation of analyzed data
All flow cytometries were performed in triplicate,
whereas the QBlue test was done up to eight times per
dose and radiation mode. For both experimental techni-
ques, dose-response data were evaluated using a stan-
dard two-factor analysis of variance (ANOVA) test in
order to analyze the effect of the dose, radiation mode,
as well as the interaction between them. Further com-
parisons among the 7 doses for each mode of irradiation
were Bonferroni corrected using GraphPad Prism. A
value of p > 0.05 was used to indicate no-significant dif-
ferences (ns), whereas asterisks denote the following
cutoff differences between the groups: *p < 0.05, **p <
0.001, ***p < 0.0001.
Results for control cells (without any radiation treat-
ment) obtained from flow cytometries were fitted as
having 100% of survival and 0% of both, death and early
apoptotic indexes. The values for the rest of the cellular
populations obtained from flow cytometric analyses
were normalized to the control group.
Results
In this section, results concerning the cell survival ratio
analyzed by flow cytometry 48 hours following the treat-
ments are presented first. In the second part, data
obtained from the QBlue assays on days 3, 4, and 9
after both, MBRT and BB, are shown.
Flow Cytometry data
Normalized data for unstained surviving cells (Table 3),
and plotted in histograms in Figure 2A, indicated the
same dose-response for both kind of irradiations. Com-
mon observations are: i) a significant decrease in survi-
val for cells irradiated up to 12 Gy, and ii) the same
percentage of living cells for doses higher than 12 Gy
(Table 3). For these data, the endpoint could be estab-
lished around 12 Gy (by flow cytometry) after both irra-
diation modes. The same conclusion can be reached by
evaluating altogether apoptotic and necrotic cells as a
function of dose (Figure 2-D), where a significant
increase in cell death is achieved from doses ≥ 12 Gy.
However, one of the most interesting findings was the
significant increase (p < 0.0001) of cells undergoing
Table 2 Doses assessed by the seamless irradiation:
Dose (Gy) 6 12 18 24 30 40
Doses (standard error, SE = ± 5%) delivered with the seamless radiation. Note
that these doses are the same than the valley doses in the case of
minibeams.
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early apoptosis 48 hours after MBRT compared to BB
(Figure 2B and Table 4). MBRT led to a clear increase
in the number of pre-apoptotic cells up to a maximum
reached at 12 Gy, remaining unchanged until 18 Gy.
Only at higher valley doses (≥ 24 Gy) the percentage of
pre-apoptotic cells decreased (Table 4), showing the
preference of F98 cells of dying by necrosis (or late
apoptosis) at those valley doses.
Figure 2C and Table 5 depicted the normalized per-
centage of cells undergoing late apoptosis and necrosis
48 hours after treatments. In the case of minibeams, a
stepwise increase in the number of dead cells was
Table 3 Normalized values for surviving cells.
Seamless and valley doses
(Gy)
% of normalized surviving cells after Minibeams
(MBRT)
(Mean ± SE)
% of normalized surviving cells after Broad Beam
(BB)
(Mean ± SE)
0 100 100
6 80.9 ± 5.6 91.2 ± 4.5
12 63.8 ± 3.3 72.7 ± 9.4
18 65.1 ± 9.2 69.6 ± 9.5
24 62.1 ± 7.5 76.0 ± 10.4
30 61.1 ± 4.0 71.4 ± 7.6
40 60.3 ± 2.4 71.5 ± 2.4
These values are represented in histograms in Figure 2A
Percentages of normalized values (mean percentage ± standard error) for surviving cells analyzed by flow cytometry 2 days after MBRT (valley doses) and BB.
These data are graphically represented in histograms in Figure 2A.
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Figure 2 (A-D) - Flow cytometry results. Normalized histograms obtained by flow cytometry 48 hours after irradiation at several doses, with
MBRT (left) and BB (right). The plots correspond to: (A) the unstained surviving cells, (B) the positive green fluorescence cells, corresponding to
those cells undergoing apoptosis in an early stage, (C) double stained cells, with propidium iodide and annexin, indicating as late apoptotic as
necrotic dead cells, and (D) the early (in green) and late (in green and red) apoptotic cells, in order to represent altogether the different death
processes.
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observed up to a valley dose of 18 Gy. Note that in this
case the percentage of dead cells at 12 Gy was practi-
cally the same (p > 0.05) than at 18 Gy (Table 5).
No significant differences were observed for doses ran-
ged from 24 Gy to 40 Gy, neither among them nor in
comparison with dead cells irradiated between 12 Gy
and 40 Gy with BB. Hence, the percentages of cell death
at higher doses seemed not to significantly differ (p >
0.05) according the radiation feature.
Therefore, the lower percentage of living cells
observed 48 hours after MBRT led to assess a higher
effectiveness of minibeams against tumor cells (p =
0.0002), although for both irradiation schemes the end-
point analyzed by flow cytometry was established
around 12 Gy.
In addition, the process of cell death clearly differed as
a function of dose, as well as of the synchrotron radia-
tion mode.
Metabolic response analyzed by QBlue assay
The cellular recovery, analyzed as metabolic activity of
living cells, was measured following a kinetic by using
the non-toxic QBlue assay.
The first measurement was performed at the third
day after treatments, when the non-irradiated cells
already showed a clear higher recovery than those irra-
diated either with minibeams or with seamless config-
uration (Figure 3E). Among the irradiated cells, the
only significant increase of the metabolic activity was
observed in cells irradiated with broad beam at 6 Gy
(Figure 3E).
This larger cell recovery observed at the third day
after BB irradiation was in agreement with the also
higher percentage of surviving cells obtained by flow
cytometry one day before.
The QBlue assay performed at the fourth day showed
once more that the largest recovery ability was for those
cells irradiated with broad beam at doses ≤ 12 Gy (Fig-
ure 3F).
Although cell recovery was larger after BB irradiation
than those observed after MBRT, the endpoint for both
irradiation modes was observed around 18 Gy. It was
due to the lack of metabolic activity for doses ≥ 18 Gy
in any mode of irradiation.
This result was also confirmed by the last QBlue mea-
surement carried out on day nine (Figure 3G). More-
over, in this last test, a complete cell recovery was
observed for cells irradiated at doses equal or lower
than 12 Gy. Under these conditions, viable cells took
profit of free space between them to reach confluence,
Table 4 Normalized values for early apoptotic cells.
Seamless and valley doses
(Gy)
% of normalized early apoptotic cells after Minibeams
(MBRT)
(Mean ± SE)
% of normalized early apoptotic cells after Broad
Beam (BB)
(Mean ± SE)
0 0 0
6 7.0 ± 1.0 5.2 ± 0.8
12 16.6 ± 3.6 2.2 ± 1.1
18 19.9 ± 4.7 0.4 ± 0.1
24 14.1 ± 1.9 0.6 ± 0.2
30 10.7 ± 2.2 2.6 ± 0.3
40 13.3 ± 3.2 2.9 ± 0.9
These values are represented in histograms in Figure 2B.
Percentages of normalized values (mean percentage ± standard error) for early apoptotic cells analyzed by flow cytometry 2 days after MBRT (valley doses) and
BB. These data are graphically represented in histograms in Figure 2B.
Table 5 Normalized values for dead cells.
Seamless and valley doses (Gy) % of normalized dead cells after Minibeams (MBRT)
(Mean ± SE)
% of normalized dead cells after Broad Beam (BB)
(Mean ± SE)
0 0 0
6 12.2 ± 0.8 3.4 ± 0.2
12 19.7 ± 2.4 25.0 ± 2.9
18 15.1 ± 1.0 30.0 ± 1.7
24 23.8 ± 0.8 24.7 ± 4.1
30 28.2 ± 1.2 26.1 ± 3.3
40 26.5 ± 2.4 25.6 ± 2.2
These values are represented in histograms in Figure 2C.
Percentages of normalized values (mean percentage ± standard error) for dead cells, including late apoptotic and necrotic cells analyzed by flow cytometry 2
days after MBRT (valley doses) and BB. These data are graphically represented in histograms in Figure 2C.
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leading to arbitrary variations in the measurement of
their metabolic activity as those shown in Figure 3G.
Hence, thanks to this additional method of measuring
viability, it was possible to check that for both synchro-
tron irradiations, doses as high as 18 Gy should be
deposited on F98 cells to avoid their recovery with time.
Discussion
Flow cytometry is widely used in studies of cell popula-
tions, because it provides information about both cell
size and intracellular structure on each cell as the sus-
pension passess at high speed through a laser beam
[22]. Furthermore, it offers the unique possibility of
multiparametric analysis, including identification and
quantitation of apoptotic and necrotic cells after
treatments.
Exploiting this technique, we could establish that the
ratio of F98 glioma cells in early stages of apoptosis was
larger when cells have been previously irradiated with
MBRT than with BB. Considering that the analyses were
performed two days after irradiation, this several-times
larger increase in apoptotic index may either indicate
that: i) there was a larger amount of cells dying by
apoptosis by this time, compared to those seamless-irra-
diated, or ii) the same number of cells were dying, but
the duration of apoptosis was more prolonged after
MBRT [23].
The first hypothesis is more likely to be the right one,
taking into account the considerable amount of pub-
lished data [15,21,23] reporting that necrotic form of
cell death is associated with acute cell injury, whereas
apoptosis is gene directered, triggered in some cases as
an adaptative response to the spatially fractionated cell
irradiation [24-26].
By studying the nuclear cell morphology, Dilmanian et
al. [24] detected in cell-culture microbeam studies that
the mode of cell death following very-high-dose irradia-
tions was by apoptotis. Nevertheless, those studies
should be applied not only for healthy but also for
tumor cells and further experiments are needed to clar-
ify the point concerning the larger ratio of cells under-
going early apoptosis after MBRT.
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Figure 3 (E-G) - Results from the QBlue tests. Normalized histograms after synchrotron MBRT (left) and BB (right) at several doses. The plots
correspond to QBlue tests performed on (E) day 3, (F) day 4, and (G) day 9 after radiations. The most significant cell recovery could be observed
at the nineth day for doses ≤ 12 Gy.
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On the other hand, two times higher valley doses
(≥24 Gy ) were needed with MBRT to reach the same
percentage of late apoptotic and necrotic cells than
those irradiated with a broad-beam configuration.
Despite this, cells irradiated with MBRT showed higher
ratios of early apoptosis in any dose with respect to BB
(Figure 2D). This fact indicates that MBRT provides a
higher effectiveness in terms of cell killing, as observed
in those plots corresponding to flow cytometries (see
Results).
The endpoint measured in terms of cell survival could
be established just before 12 Gy for both irradiation
modes.
Nevertheless, the effectiveness on tumor cells of both,
MBRT and BB irradiations, cannot be assessed exclu-
sively by the death of cells after treatment analyzed by
flow cytometry, and other biophysical aspects such as
the recovery ability with time have also to be consid-
ered. For this purpose, a complementary technique to
flow cytometry was used. It allows to measure the
recovery of the remaining living cells after each irradia-
tion. In contrast to others such as the (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), QBlue test provides an adequate estimation of
cell proliferation, keeping the cells alive. In this way, a
kinetic study can be performed. In addition, Alamar
QBlue is more sensitive than MTT [27].
The results from the second technique points at
around 18 Gy the endpoint for MBRT and BB. This
endpoint corresponds to the dose from which there was
not observed any cell recovery with time. This new
threshold obtained by the QBlue tests is higher than
those assessed by flow cytometry, where cell recovery
was not taken into account. Hence, this highlights the
need to use at least two techniques to study the effec-
tiveness of a treatment. Going further, those techniques
should be complementary in order to obtain a more
valuable results. In this way, the data obtained from
flow cytometric analysis can be perfectly complemented
with different QBlue tests performed with time.
A clonogenic assay was performed after minibeam cell
irradiation. Despite not showing the data due to the fact
that this assay was not performed at least three times as
the other techniques, the threshold dose obtained was
18-Gy valley dose for MBRT. This endpoint was the
same that the one assessed previously by using the
QBlue test.
In addition, Sarun et al. (paper in preparation)
encountered that the valley dose threshold was around
20 Gy for a more radioresistant cell line (9L) irradiated
with minibeams. This endpoint assessed by QBlue at 20
Gy agrees with those established around 18 Gy for the
more radiosensitive F98 cell line [16,17].
Conclusions
In our work we found a higher efficiency of MBRT in
respect to BB for F98 cell-irradiation, mainly due to the
large ratio of remaining early apoptotic cells, as well as
a lower cell recovery than those obtained with a broad
field.
Hence, we have demonstrated that considering only
the ratio of dead cells (necrotic and late apoptotic cells)
is not sufficient to assess the effectiveness of a radiation
treatment, and parameters like the percentage of early
apoptotic cells as well as the cellular recovery at several
post-irradiation times should also be considered.
In addition, although further studies are needed,
MBRT might offer probably a remarkable healthy tissue
sparing in comparison to BB, as already observed in
some first experiments [13].
Acknowledgements
The authors thank Alberto Bravin and the team of ID17 of the European
Synchrotron Radiation Facility (ESRF) for the granted beamtime.
This work was supported by “Federación Catalana de la Asociación Española
Contra el Cáncer” grant.
Author details
1Centre d’Estudis en Biofísica, Faculty of Medicine, Autonomous University of
Barcelona, Cerdanyola del Vallès, Spain. 2European Synchrotron Radiation
Facility (ESRF), Grenoble, France. 3Hospital Clínic, University of Barcelona,
Barcelona, Spain.
Authors’ contributions
SG: participated in the design of the study, prepared the samples for
irradiations, carried out all the post-irradiation techniques, performed the
statistical analysis, and wrote the main part of the manuscript.
SS: participated in the coordination, helped preparing the samples for
irradiations and with the performance of QBlue test, and helped to draft the
manuscript.
AB: helped to draft the manuscript.
YP: carried out all the dose calculations and sample irradiations, participated
in the design and coordination of the experiments and helped to draft the
manuscript.
MS: participated in the design and coordination of the experiments and
helped to draft the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 January 2011 Accepted: 13 April 2011
Published: 13 April 2011
References
1. Legler JM, Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, Linet MS:
Brain and other central nervous system cancers: recent trends in
incidence and mortality. J. Natl. Cancer Inst 1999, 91:1382-90.
2. Poncelet BP, Wedeen VJ, Weisskoff RM, Cohen MS: Brain parenchyma
motion: measurement with cine echo-planar MR imaging. Radiology
1992, 185:645-651.
3. Curtis HJ: The use of a deuteron microbeam for simulating the biological
effects of heavy cosmic-ray particles. Radiat. Res. Suppl 1967, 7:258-264.
4. Siegbahn EA, Stepanek J, Bräuer-Krisch E, Bravin A: Determination of
dosimetrical quantities used in microbeam radiation therapy (MRT) with
Monte Carlo simulations. Med. Phys 2006, 33:3248-3259.
5. Prezado Y, Thengumpallil S, Renier M, Bravin A: X-ray energy optimization
in minibeam radiation therapy. Med. Phys 2009, 36:4897-4902.
Gil et al. Radiation Oncology 2011, 6:37
http://www.ro-journal.com/content/6/1/37
Page 8 of 9
6. Slatkin DN, Spanne P, Dilmanian FA, Gebbers JO, Laissue JA: Subacute
neuropathological effects on rats of microplanar beams of x-rays from a
synchrotron wiggler. Proc. Natl. Acad. Sci. USA 1995, 92:8783-8787.
7. Regnard P, Le Duc G, Bräuer-Krisch E, Troprès I, Siegbahn EA, Kusak A,
Clair C, Bernard H, Dallery D, Laissue JA, Bravin A: Irradiation of
intracerebral 9L gliosarcoma by a single array of microplanar X-ray
beams from a synchrotron: balance between curing and sparing. Phys.
Med. Biol 2008, 53:861-878.
8. Laissue JA, Geiser G, Spanne PO, Dilmanian FA, Gebbers JO, Geiser M,
Wu XY, Makar MS, Micca PL, Nawrocky MM, Joel DD, Slatkin DN:
Neuropathology of ablation of rat gliosarcomas and contiguous brain
tissues using a microplanar beam of synchrotron-wiggler-generated X
rays. Int. J. Cancer 1998, 78:654-660.
9. Laissue JA, Blattmann H, Michiel MD, Slatkin , Lyubimova N, Guzman R,
Zimmermann W, Birrer S, Bley T, Kircher P, Stettler R, Fatzer R, Jaggy A,
Smilowitz H, Brauer E, Bravin A, Le Duc G, Nemoz C, Renier M,
Thomlinson WC, Stepanek J, Wagner HP: The weanling piglet cerebellum:
a surrogate for tolerance to MRT (microbeam radiation therapy) in
pediatric neurooncology. Proc. of SPIE 2001, 4508:65-73.
10. Dilmanian FA, Morris GM, Le Duc G, Huang X, Ren B, Bacarian T, Allen JC,
Kalef-Ezra J, Orion I, Rosen EM, Sandhu T, Sathé P, Wu XY, Zhong Z,
Shivaprasad HL: Response of avian embryonic brain to spatially
segmented X-ray microbeams. Cell. Mol. Biol 2001, 47:485-493.
11. Dilmanian FA, Button TM, Le Duc G, Zhong N, Pena LA, Smith JAL,
Martinez SR, Bacarian T, Tammam J, Ren B, Farmer PM, Kalef-Ezra J,
Micca PL, Nawrocky MM, Niederer JA, Recksiek FP, Fuchs A, Rosen EM:
Response of rat intracranial 9L gliosarcoma to microbeam radiation
therapy. J. Neurooncol 2002, 4:26-38.
12. Smilowitz HM, Blattmann H, Bräuer-Krisch E, Bravin A, Di Michiel M,
Gebbers JO, Hanson AL, Lyubimova N, Slatkin DN, Stepanek J, Laissue JA:
Synergy of gene mediated immunoprophylaxis and microbeam
radiation therapy for advanced intracraneal rat 9L gliosarcomas. J.
Neurooncol 2006, 78:135-143.
13. Dilmanian FA, Zhong Z, Bacarian T, Benvenlste H, Romanelli P, Wang R,
Welwart J, Yuasa T, Rosen EM, Anschel DJ: Interlaced X-ray microplanar
beams: a radiosurgery approach with clinical potential. Proc. Natl. Acad.
Sci. USA 2006, 103:9709-9714.
14. Prezado Y, Renier M, Bravin A: A new method of creating minibeam
patterns for synchrotron radiation therapy: a feasibility study. J.
Synchrotron Rad 2009, 16:582-586.
15. Gorczyca W: Cytometric analyses to distinguish death processes.
Endocrine-Related Cancer 1999, 6:17-19.
16. Barth RF: Rat brain tumor models in experimental neuro-oncology: The
9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 Gliomas. J. Neurooncol 1998,
36:91-102.
17. Bencokova Z, Pauron L, Devic C, Joubert A, Gastaldo J, Massart C, Balosso J,
Foray N: Molecular and cellular response of the most extensively used
rodent glioma models to radiation and/or cisplatin. J. Neurooncol 2008,
86:13-21.
18. Menichetti L, Gaetano L, Zampolli A, Del Turco S, Ferrari C, Bortolussi S,
Stella S, Altieri S, Salvadori PA, Cionini L: In vitro neutron irradiation of
glioma and endothelial cultured cells. Appl Radiat. Isot 2009, 67:336-340.
19. Salvat F, Fernández-Varea JM, Sempau J: PENELOPE, a code system for
Monte Carlo Simulation of electron and photon transport. OECD Nuclear
Energy Agency (Issy-les-Moulineaux-France) 2003 [http://www.nea.fr].
20. Serduc R, Bouchet A, Bräuer-Krisch E, Laissue JA, Spiga J, Sarun S, Bravin A,
Fonta C, Renaud L, Boutonnat J, Siegbahn EA, Estève F, Le Duc G:
Synchrotron microbeam radiation therapy for rat brain tumor palliation–
influence of the microbeam width at constant valley dose. Phys. Med.
Biol 2009, 54:6711-6724.
21. Amirlak B, Couldwell W: Apoptosis in glioma cells: review and analysis of
techniques used for study with focus on the laser scanning cytometer. J.
Neurooncol 2003, 63:129-145.
22. Ormerod MG: Flow cytometry: A Practical Approach.Edited by: American
Chemical Society 2000.
23. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F:
Cytometry in cell necrobiology: Analysis of apoptosis and accidental
death (necrosis). Cytometry 1997, 27:1-20.
24. Dilmanian FA, Qu Y, Feinendegen LE, Peña LA, Bacarian T, Henn FA, Kalef-
Ezra J, Liu S, Zhong Z, McDonald JW: Tissue-sparing effect of X-ray
microplanar beams particularly in the CNS: is a bystander effect
involved? Exp. Hematol 2007, 35:69-77.
25. Feinendegen LE: Relative implications of protective responses versus
damage induction at low-dose and low-dose rate exposures, using the
microdose approach. Radiat. Prot. Dosimetry 2003, 104:337-346.
26. Feinendegen LE, Pollycove M, Sondhaus CA: Response to low doses of
ionizing radiation in biological systems. Nonlinearity Biol. Toxicol. Med
2004, 2:143-171.
27. O’Brien J, Wilson I, Orton T, Pognan F: Investigation of the Alamar Blue
(resazurin) fluorescent dye for the assessment of mammalian cell
cytotoxicity. Eur. J. Biochem 2000, 267:5421-5426.
doi:10.1186/1748-717X-6-37
Cite this article as: Gil et al.: Survival Analysis of F98 Glioma Rat Cells
Following Minibeam or Broad-Beam Synchrotron Radiation Therapy.
Radiation Oncology 2011 6:37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gil et al. Radiation Oncology 2011, 6:37
http://www.ro-journal.com/content/6/1/37
Page 9 of 9
